Diuresis pathway modulation

Diuresis pathway modulation refers to the therapeutic targeting of physiological processes that control urine production, mainly through the regulation of sodium and water reabsorption in the kidneys. This process is influenced by multiple molecular targets, including sodium-chloride cotransporter (SLC12A3, thiazide-sensitive), sodium-potassium-chloride cotransporter (NKCC2, SLC12A1, loop diuretic target), potassium channels (KCNJ1), chloride channels (CLCNKA, CLCNKB), as well as regulatory kinases and hormonal systems such as the renin-angiotensin-aldosterone system and antidiuretic hormone. Diuretics act at different nephron sites to inhibit these pathways, affecting fluid and electrolyte excretion and thus are essential in the treatment of fluid-overload conditions such as heart failure, hypertension, and chronic kidney disease[1][3][6]. This entry represents a pathway or pharmacological concept, not a canonical single molecular entity or target, and thus should not be treated as a direct molecular drug target[1][5][6].

Inhibition of renal sodium transporters (such as sodium-potassium-chloride cotransporter NKCC2 and sodium-chloride cotransporter SLC12A3); Alteration of renal prostaglandin synthesis; Modulation of renin-angiotensin-aldosterone system